comprehensive -WSS

comprehensive

author：comprehensive 2025-08-28 13:06:09 - browse：299

Gavel and Stethoscope due process — District courts will make the first round of decisions soon on challenges to Medicare's drug price negotiation program. APStock

WASHINGTON — Pharmaceutical companies’ efforts to scuttle President Biden’s signature health care achievement, empowering Medicare to negotiate prescription drug prices, will soon face their first big tests.

District court judges could soon weigh in on the litany of court cases that major companies filed against the government — shedding light on whether drugmakers have any hope of postponing the first parts of the negotiation process, scrapping it entirely, or sending the issue up to the Supreme Court.

It’s a major moment for the Biden administration, too, as the White House ramps up its efforts to take credit for the new changes in the 2024 election. The first round of legal decisions will play out in the thick of campaign season, attorneys told STAT.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： Activists slam private health insurers over coverage restrictions
Next article： Reconstructing family trees of blood cells may help predict disease

WSS

White House pharmacy plagued with problems, investigation finds

Humana’s losses in Medicare Advantage tank its stock

Syphilis numbers in the United States reach record heights

The latest on Bluebird gene therapies, Vertex's pain drug, and ADC FOMO

Biogen walks away from Aduhelm, years after polarizing approval

The latest on Bluebird gene therapies, Vertex's pain drug, and ADC FOMO

explore

comprehensive

focus

What does generative AI mean for health care? We asked experts

White House pharmacy plagued with problems, investigation finds

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

The latest on Bluebird gene therapies, Vertex's pain drug, and ADC FOMO

Alkermes shareholders re

Health Care Service Corp to buy Cigna Medicare Advantage plans

As demand for Covid shots wanes, Moderna seeks its next success

How generative AI ratchets up security threats for health systems

How to save PrEP access — and even expand it

White House pharmacy plagued with problems, investigation finds

hotspot

Wegovy leads to weight loss. Can it treat depression, too?

The latest on Bluebird gene therapies, Vertex's pain drug, and ADC FOMO

White House pharmacy plagued with problems, investigation finds

White House pharmacy plagued with problems, investigation finds

The latest on Bluebird gene therapies, Vertex's pain drug, and ADC FOMO

Merck CEO won’t testify in Senate, citing no expertise in drug prices

leisure time

explore

Wikipedia

focus